Ginkgo Bioworks Holdings Inc (DNA)
0.9237
+0.05
(+5.98%)
USD |
NYSE |
Apr 18, 16:00
0.91
-0.01
(-1.48%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.988B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -28.56% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.144 |
| Price to Book Value | 1.812 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
| URL | https://www.ginkgobioworks.com |
| Investor Relations URL | https://investors.ginkgobioworks.com/ |
| HQ State/Province | Massachusetts |
| Sector | Materials |
| Industry | Chemicals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
| URL | https://www.ginkgobioworks.com |
| Investor Relations URL | https://investors.ginkgobioworks.com/ |
| HQ State/Province | Massachusetts |
| Sector | Materials |
| Industry | Chemicals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Feb. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |